poisar

Stocks · News reference

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency

Benzinga Newsdesk

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CODXEBSGILDGOVXINOJNJMRKMRNANNVCOSURREGNSPY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

    A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

    AMGNPFENVSGILDREGN
  2. Delveinsight

    Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

    The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

    JNJMLTXABBVAMGNTAK
  4. Dana George

    The Investing Playbook for Retirees Who Can't Afford to Lose

    The article provides a strategic framework for retirees on fixed incomes to protect their savings while managing inflation risk. It recommends a three-bucket approach: maintaining 12-24 months of expenses in cash/short-term fixed income, holding inflation-beating investments with dividend stocks, and allocating remaining funds to long-term growth stocks. The strategy emphasizes identifying essential expenses, calculating guaranteed income gaps, and using bond ladders and high-yield savings accounts to avoid forced asset sales during market downturns.

    JNJMAKO
  6. David Jagielski, Cpa

    The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?

    The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.

    SCHDMRKABTAMGN